PDL BioPharma, Inc.
PDLI
PDLI was delisted on the 30th of December, 2020.
171 hedge funds and large institutions have $322M invested in PDL BioPharma, Inc. in 2017 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 38 increasing their positions, 71 reducing their positions, and 16 closing their positions.
153% more call options, than puts
Call options by funds: $476K | Put options by funds: $188K
6% more capital invested
Capital invested by funds: $304M → $322M (+$18M)
2% less funds holding
Funds holding: 174 → 171 (-3)
13% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 16
46% less repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 71
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
+$4.01M |
| 2 |
KIM
Kestrel Investment Management
San Mateo,
California
|
+$4M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$3.82M |
| 4 |
BIP
Brandes Investment Partners
La Jolla,
California
|
+$2.41M |
| 5 |
Fuller & Thaler Asset Management
San Mateo,
California
|
+$2.31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$4.16M |
| 2 |
Morgan Stanley
New York
|
-$3.23M |
| 3 |
Renaissance Technologies
New York
|
-$3.06M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.01M |
| 5 |
Mackenzie Financial
Toronto Ontario,
Ontario, Canada
|
-$2.69M |
PDLI Hedge Fund Activity: Q2 2017 in Review
171 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in PDL BioPharma, Inc. (PDLI) for Q2 2017, worth a combined $322M — up 5.9% from $304M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of PDLI and 14 opened new positions — a net loss of 2 holders — while 71 trimmed existing stakes and 38 added.
The largest buyer was Dimensional Fund Advisors, adding an estimated $4.01M. The largest seller was Citadel Advisors, cutting an estimated $4.16M.
- 171 institutional investors held PDL BioPharma, Inc. (PDLI) as of Q2 2017, down from 174 in Q1 2017.
- Funds reported $322M of PDL BioPharma, Inc. stock for Q2 2017, up 5.9% quarter-over-quarter.
- 14 funds opened new PDL BioPharma, Inc. positions in Q2 2017 and 16 closed out, a net change of -2 holders.
- The largest PDL BioPharma, Inc. buyer in Q2 2017 was Dimensional Fund Advisors, an estimated $4.01M added.
- The largest PDL BioPharma, Inc. seller in Q2 2017 was Citadel Advisors, an estimated $4.16M sold.
Based on aggregated 13F filings for Q2 2017.